Pan-Latin American specialty pharmaceutical company focused on oncology and critical care drugs

Rapidly growing pan-Latin American specialty pharmaceutical company

Biotoscana is a pan-Latin American specialty pharmaceutical company, headquartered in Bogotá, Colombia with operations across the region and a broad portfolio of specialty pharmaceutical products as well as generics. Biotoscana was founded as a family owned business in 1994 and expanded across the region, with operations in Colombia, Brazil, Argentina, Chile, Ecuador and Peru. Biotoscana expanded into Brazil in 2014 when it agreed to acquire United Medical, a specialty pharma company focused on therapies to serve significant unmet needs. The company sold a mixture of specialty pharmaceuticals and branded generics and increasingly focused on growing the specialty pharmaceutical business with novel, high-value products in-licensed from global pharmaceutical companies.

Essex Woodlands, together with Advent International, a Latin American private equity company, acquired a controlling stake in Biotoscana at the end of 2011. In November 2019, Knight Therapeutics completed the acquisition of a controlling interest in Biotoscana for C$187 in cash consideration for this controlling interest.

  • Bogota, Colombia

  • Contact:
    Evis Hursever
  • Acquisition
  • Acquired by: Knight Therapeutics
  • Logo

Related News

“Essex’s deep healthcare expertise, industry relationships and strategic insights are helping Biotoscana achieve its mission of being the high growth specialty pharma company in Latin America.”

Mariano Garcia-Valino

CEO, Biotoscana

Testimonials and endorsements reflect portfolio company management’s opinions and beliefs regarding the company and the investment. Such opinions and beliefs are subjective, do not represent a complete assessment of the company, the market or EW’s overall investment performance and cannot be independently verified. Such statements are being offered as references for purposes of demonstrating the benefits of working with the EW team and not for the purpose of soliciting investors. Portfolio company executives receive/received a salary and economics from the portfolio company. No executives were paid for their testimonial or endorsement. There is a conflict of interest in these unpaid testimonials and endorsements in that all speakers stand to benefit from EW’s success and they work/worked for an EW portfolio company.